$NVDA NEWS Nvidia stock tumbles as new Biden rule threatens new curbs on chip exports BSE - Delayed Quote • INR Shilchar Technologies Limited (SHILCTECH.BO) Follow Compare 7,906.35 -416.10 (-5.00%) At close: 3:58:27 PM GMT+5:30 Related News Cleveland-Cliffs, Nucor reportedly plan offer to buy US Steel Cleveland-Cliffs (CLF) and Nucor (NUE) are reportedly planning an all-cash offer for US Steel (X), according to reports from CNBC. The reports come after the Biden administration blocked the sale of US Steel to Japanese steel-making giant Nippon Steel. Senior Markets Reporter Ines Ferré joins Catalysts co-hosts Seana Smith and Madison Mills to break down the reported deal and what it means for US Steel. To watch more expert insights and analysis on the latest market action, check out more Catalysts here. This post was written by Naomi Buchanan. Moderna cuts sales forecast on weaker vaccine demand Moderna shares slumped Monday on the company's downgraded 2025 outlook. Moderna Crashes 21%. 'No Inflection In Sight' After Guidance Cut, CMV Shortfall. Moderna stock crashed Monday after the firm slashed its outlooks for 2024 and 2025, and announced an expanded cost-cutting initiative. Abercrombie and Fitch (ANF) Stock Trades Down, Here Is Why Shares of young adult apparel retailer Abercrombie & Fitch (NYSE:ANF) fell 19.9% in the morning session after the company reported underwhelming sales and earnings forecasts, falling short of high expectations for retail stocks fueled by strong demand ahead of the holiday shopping season. ANF bumped its sales growth outlook for Q4 2024 to a range of 7-8% from a prior range of 5-7%. However, this modest increase lags far behind the robust double-digit growth the company achieved in the same quart Cancer-Focused Phio Pharmaceuticals Stock Gains 300% On Monday - Here's Why On Monday, Phio Pharmaceuticals Corp. (NASDAQ:PHIO) stock skyrocketed with a strong session volume of 201.04 million, compared to the average volume of 362.72k, according to data from Benzinga Pro. Phio reported pathologic responses for patients enrolled in the 2nd cohort, which includes two patients with a complete response or 100% tumor clearance. Phio’s ongoing Phase 1b clinical study is designed to evaluate the safety and tolerability of neoadjuvant use of intratumoral PH-762 in Stages 1, 2 Cleveland-Cliffs and Nucor plan joint bid for US Steel Cleveland-Cliffs and Nucor are set to launch a joint bid to acquire US Steel just weeks after US President Joe Biden blocked the $15bn takeover... Why U.S. Steel (X) Stock Is Climbing Today United States Steel (X) stock is advancing 8.5% today after it was reported that two American steel firms are interested in buying it. Also importantly, the Biden administration delayed the implementation of its order which would kill a proposed takeover of X by Japan’s Nippon Steel (NPSCY). Cleveland Cliffs Is Reportedly Interested in Buying X […] Stock Market Today: Dow Jones Up; This Stock Soars On Bill Ackman Offer, But 2024 Winner Hammered (Live Coverage) The Dow Jones rose even as other indexes fell on the stock market today. Nvidia swooned on a Biden AI move. Bill Ackman made an offer. J&J Announces A Splashy $14.6 Billion Deal, While Lilly Tacks On A Cancer Drug Johnson & Johnson kicked off the J.P. Morgan Healthcare Conference on Monday with the $14.6 billion acquisition of Intra-Cellular Therapies. Top Stock Movers Now: Moderna, Macy's, Valero Energy, and More U.S. equities were mixed at midday, with the Nasdaq losing more than 1% on worries about future Federal Reserve interest-rate cuts. Top Midday Stories: Moderna Shares Fall After 2025 Revenue Guidance Cut; Cleveland-Cliffs Reportedly Teams Up With Nucor in Potential Bid for US Steel The three major US stock indexes were mixed around midday Monday, the first trading day after the re A Mixed Bag of Factors Influencing Moderna's Stock This Month Moderna's Stock Roller Coaster: From Highs to Lows Moderna's $1 Billion Revenue Forecast Cut Sends Stock Plummeting Over 20% Moderna shares plunged Monday after the company cut its 2025 revenue forecast by $1 billion. Why Moderna Stock Just Crashed 21% Moderna's (NASDAQ: MRNA) sales are slowing down, and Moderna stock is going down -- a lot. The coronavirus vaccine maker's shares plunged 21.2% through 10:20 a.m. ET Monday after it updated investors on its 2024 performance and released new guidance for 2025. Moderna estimates it ended 2024 with somewhere between $3 billion and $3.1 billion in product sales as it shifted its business toward treating COVID-19 as an "endemic" illness rather than a novel and spreading pandemic. ITCI Stock Rises 15% on Settling Caplyta Patent Litigation With Sandoz Intra-Cellular stock gains 15% as it settles Caplyta patent litigation with Sandoz protecting the drug's exclusivity in the United States till July 1, 2040. Cleveland-Cliffs partners with Nucor to potentially bid for US Steel, CNBC reports Cleveland-Cliffs is partnering with peer Nucor to prepare a potential bid for U.S. Steel, CNBC reported on Monday, citing sources. According to the report, Cleveland-Cliffs would purchase U.S. Steel in an all-cash deal and then sell the company's Big River Steel subsidiary to Nucor. U.S. Steel's headquarters would remain in Pittsburgh under the deal, the CNBC report said. These Stocks Are Moving the Most Today: Nvidia, Tesla, Moderna, Intra-Cellular Therapies, D-Wave Quantum, Edison, U.S. Steel, and More Nvidia pushes back on new artificial-intelligence regulations, Tesla stock trades lower, Moderna issues weak revenue guidance, and Intra-Cellular Therapies is being acquired by Johnson & Johnson for nearly $15 billion. Abercrombie & Fitch Lifts Its Outlook—And Its Stock Drops Apparel retailer Abercrombie & Fitch lifted its end-of-year outlook today, but its shares were down nearly 20% in recent trading. Abercrombie Stock Is Having Its Worst Day in Years. An Analyst Sees a Buying Opportunity. The retailer now sees net sales increasing between 7% and 8% from last year after a record holiday season. Moderna's Stock Crashes 22%--Pandemic Hero Now Fighting for Survival Revenue forecasts slashed, vaccine sales dive, and Wall Street loses patience--can Moderna bounce back? Performance Overview Trailing total returns as of 1/13/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX Return SHILCTECH.BO S&P BSE SENSEX YTD +3.55% -2.45% 1-Year +3.55% +5.18% 3-Year +3.55% +24.82%